Table 1.
Comparison of patient characteristics, treatment, and outcomes between the two waves.
| Total | First wave | Second wave | p-value |
|---|---|---|---|
| 241 | 185 | ||
| Age (years) | 66 ± 15.75 | 70.4 ± 16.5 | 0.06 |
| Under 40 | 16 | 9 | |
| 40–70 | 115 | 70 | |
| Above 70 | 110 | 106 | |
| Body mass index (BMI) (kg/m2) | 30.3 ± 7 | 29.3 ± 8.4 | 0.045 |
| <18.5 | 3 | 9 | |
| 18.5–24.9 | 52 | 56 | |
| 25–29.9 | 76 | 54 | |
| 30–34.9 | 58 | 33 | |
| 35–39.9 | 28 | 15 | |
| ≥40 | 24 | 18 | |
| African american (AA) race n (%) | 23 (10) | 15 (8) | 0.61 |
| Females n (%) | 83 (34) | 79 (43) | 0.08 |
|
| |||
| Past medical history n (%) | |||
| Diabetes | 103 (43) | 72 (39) | 0.43 |
| Hypertension | 160 (66) | 127 (69) | 0.62 |
| Cardiovascular disease | 74 (31) | 92 (50) | <0.01 |
| Chronic kidney disease | 31 (13) | 34 (18) | 0.12 |
|
| |||
| COVID-19 directed treatment n (%) | |||
| Remdesivir | 48 (20) | 136 (74) | <0.01 |
| Dexamethasone | 13 (5) | 165 (89) | <0.01 |
| Hydroxychloroquine | 190 (79) | 2 (1) | <0.01 |
| Convalescent plasma | 41 (17) | 50 (27) | <0.01 |
|
| |||
| Clinical outcomes n (%) | |||
| Acute kidney injury (AKI) | 174 (72) | 116 (63) | 0.04 |
| Renal replacement therapy (RRT) | 62 (36) | 35 (30) | 0.1 |
| Mortality | 168 (70) | 117 (63) | 0.16 |